A phase 2b study of merimepodib in combination with pegylated interferon alfa-2a (Pegasys) [peginterferon alfa-2a] and ribavirin in subjects with chronic hepatitis C non-responsive to prior therapy with pegylated interferon alfa and ribavirin
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2009
At a glance
- Drugs Merimepodib; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms METRO
- 20 Dec 2007 Status changed from in progress to complete.
- 24 Oct 2005 New trial record.